This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Michael Lehmann Appointed Patheon's President Of Global Pharmaceutical Development Services

Stocks in this article: PTI

TORONTO, Nov. 1, 2012 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that Michael Lehmann has joined the company as President of Global Pharmaceutical Development Services (PDS).

"I am pleased to be welcoming Mike and getting him quickly integrated with Patheon's leadership team," stated James C. Mullen, Patheon's Chief Executive Officer.  "He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.  Patheon will significantly benefit from his recognized ability to drive both growth and competitiveness in varying market conditions, and I look forward to his future contributions as we continue to transform our business to provide the leading customer experience."

Mr. Lehmann was most recently Corporate Senior Vice President and General Manager of the Global Early Development business of Covance from 2005 to 2012, which is one of the world's largest drug development services companies.  In his role, he was responsible for global early development and P&L management; and key accomplishments included executive leadership in strategic deals between Covance, Lilly and Sanofi. Prior to joining Covance, Mr. Lehmann worked for 17 years at GE's Healthcare in key operational and management roles.  His career started with a focus in client services, managing large call centers for both external customers and repair technicians.  In 1998, he was tasked with assisting in the integration of the company's MECON acquisition, operational and clinical performance optimization services.  Mr. Lehmann progressed through various other comparable roles to emerge as the General Manager of the Multivendor Solutions business in 2003, where he was responsible for facilitating the upkeep and repair of other OEM diagnostic imaging equipment and accessories with complete P&L responsibilities.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,370.81 -307.89 -1.74%
S&P 500 2,027.57 -29.52 -1.44%
NASDAQ 4,686.7020 -85.0610 -1.78%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs